Fiorini G, et al. - The efficacy of 12-day rifabutin-based triple therapy was investigated in patients infected with multidrug-resistant strains of Helicobacter pylori (H. pylori). No current standard was found for the growing population of patients with multidrug-resistant strains of H. pylori. For patients infected with triple-resistant strains, the 12-day low-dose rifabutin/high-dose proton pump inhibitor regimen was found to be a safe and reliable option.